← Back to Research Radar
Academic Publication Academic Publication

Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections

182
Citations
December 1, 2024
Published Date

Research Abstract & Technology Focus

AbstractMetagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) is an agnostic method for broad-based diagnosis of central nervous system (CNS) infections. Here we analyzed the 7-year performance of clinical CSF mNGS testing of 4,828 samples from June 2016 to April 2023 performed by the University of California, San Francisco (UCSF) clinical microbiology laboratory. Overall, mNGS testing detected 797 organisms from 697 (14.4%) of 4,828 samples, consisting of 363 (45.5%) DNA viruses, 211 (26.4%) RNA viruses, 132 (16.6%) bacteria, 68 (8.5%) fungi and 23 (2.9%) parasites. We also extracted clinical and laboratory metadata from a subset of the samples (n = 1,164) from 1,053 UCSF patients. Among the 220 infectious diagnoses in this subset, 48 (21.8%) were identified by mNGS alone. The sensitivity, specificity and accuracy of mNGS testing for CNS infections were 63.1%, 99.6% and 92.9%, respectively. mNGS testing exhibited higher sensitivity (63.1%) than indirect serologic testing (28.8%) and direct detection testing from both CSF (45.9%) and non-CSF (15.0%) samples (P 
seven-year performance clinical metagenomic next-generation sequencing
Read Full Literature

Correlated Market Trend: Academic Performance

Bridging academia to market: The 60-day public search velocity mapping directly to the core technology of this paper. Dashed line represents 7-day moving average.

AI Semantic Synergy Context

Connecting this academic literature to real-world market discussions and products.

crossref.org › academic paper
98%
🔥

Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections

AbstractMetagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) is an agnostic method for broad-based diagnosis of central nervous system (CNS) infections. Here we analyzed the 7...
roipad.com › trend story
0%

Whole-genome variant detection in long-read sequencing data from ultralow input patient samples

Long-read sequencing provides a more complete view of the genome compared with short-read sequencing, with improved detection of structural variants, tandem repeats (TRs), and small variants (singl...
roipad.com › trend story
0%

Whole-genome variant detection in long-read sequencing data from ultra-low input patient samples

Long-read sequencing provides a more complete view of the genome than short-read sequencing, with improved detection of structural variants, tandem repeats, and small variants (single nucleotide va...
crossref.org › academic paper
0%

Amplification-free, OR-gated CRISPR-Cascade reaction for pathogen detection in blood samples

Rapid and accurate detection of DNA from disease-causing pathogens is essential for controlling the spread of infections and administering timely treatments. While traditional molecular diagnostics...
crossref.org › academic paper
0%

A Comprehensive Review of Bioinformatics Tools for Genomic Biomarker Discovery Driving Precision Oncology

The rapid advancement of high-throughput technologies, particularly next-generation sequencing (NGS), has revolutionized cancer research by enabling the investigation of genetic variations such as ...

Frequently Asked Questions (FAQ)

Curated market intelligence mapped to this research.

What is the core focus of the research titled 'Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections'?

This literature focuses on: AbstractMetagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) is an agnostic method for broad-based diagnosis of central nervous system (CNS) infections. Here we analyzed the 7-year performance of clinical CSF mNGS testing of ...

Are there open-source GitHub repositories related to Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections?

Yes, open-source projects like mattmireles/gemma-tuner-multimodal (Fine-tune Gemma 4 and 3n with audio, images and text on Apple Silicon, using PyTorch and Metal Performance Shaders.) are actively building upon these concepts.

Which startups are commercializing the technology behind Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections?

Products like Pixel are bringing this to market. Their focus is: Scale performance ads without juggling 7 ad platforms.

What other academic literature is closely related to 'Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections'?

Yes, highly correlated activity was mapped. An entry titled 'Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections' discusses this: AbstractMetagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) is an agnostic method for broad-based diagnosis of central nervo...

Are there commercial applications of 'Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections' in market news publications?

Yes, highly correlated activity was mapped. An entry titled 'Whole-genome variant detection in long-read sequencing data from ultralow input patient samples' discusses this: Long-read sequencing provides a more complete view of the genome compared with short-read sequencing, with improved detection of structural variant...

Cite this Market Intelligence Report

Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.

Commercial Realization

Startups and Open Source tools heavily associated with the concepts explored in this paper.

Associated Media Narrative